Care of patients with stone disease and CKD is complicated by the need for closer monitoring with medical therapy, as well as by decreased stone-free rates with a greater frequency of ...
But while the benefits of GLP-1 receptor agonists for the treatment of type 2 diabetes, obesity and cardiovascular disease are well known, their impact on chronic kidney disease (CKD) has been ...
Optimizing urate-lowering therapy to achieve target serum urate levels may not harm, and may benefit, patients with gout and CKD. Despite clinician concerns, treating patients with gout and stage 3 ...